Drugs / Cethrin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00500812 | Feb 2005 → Dec 2008 | spinal cord injury | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00610337 | — | spinal cord injury | BioAxone BioSciences, Inc. | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02053883 | Jul 2015 → May 2016 | spinal cord injury | BioAxone BioSciences, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cethrin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02053883 ↗ |
| Known as | BA-210 | “Cethrin® (BA-210)” NCT00610337 ↗1“Cethrin (BA-210)” NCT02053883 ↗ |
| Action | Inhibit | “blocks activation of Rho” PMID 21381984 ↗ May 2011 |
| Modality | Protein / enzyme biologic | “a therapeutic protein drug” PMID 23844986 ↗ Oct 2013 |
| Route | Other | “a Single Extradural Application of Cethrin” NCT00500812 ↗ |